Advertisement

Topics

NICE leans towards a ‘no’ for Keytruda in urothelial cancer

04:33 EDT 4 Aug 2017 | PharmaTimes

Cost regulators for NHS therapies in England and Wales have turned down MSD’s immunotherapy Keytruda as a treatment for locally advanced or metastatic urothelial cancer.

Original Article: NICE leans towards a ‘no’ for Keytruda in urothelial cancer

NEXT ARTICLE

More From BioPortfolio on "NICE leans towards a ‘no’ for Keytruda in urothelial cancer"

Quick Search
Advertisement
 

Relevant Topics

Biological Therapy
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...